Concorde Asset Management’s GSK GSK Stock Holding History

Concorde Asset Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-59,186	Closed	-$3.22M	–	131
2022 Q1	$3.22M	Buy	59,186 +36,232	+158%	+$1.97M	2.14%	6
2021 Q4	$1.26M	Buy	22,954 +2,476	+12%	+$129K	0.75%	44
2021 Q3	$978K	Sell	20,478 -43,334	-68%	-$2.18M	0.56%	57
2021 Q2	$3.18M	Buy	63,812 +27,570	+76%	+$1.32M	1.78%	7
2021 Q1	$1.62M	Buy	+36,242	New	+$1.64M	0.93%	31

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Concorde Asset Management's GSK Position: Q2 2022 in Review

Concorde Asset Management sold out of GSK (GSK) in Q2 2022, closing a stake of 59,186 shares — an estimated $3.22M sold.

Concorde Asset Management first reported a position in GSK in Q1 2021 and held it in 5 quarters. The position peaked at $3.22M in Q1 2022. 900 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

Concorde Asset Management reported no remaining GSK position as of Q2 2022 after selling out during the quarter.
Concorde Asset Management sold 59,186 GSK shares in Q2 2022, an estimated $3.22M.
Concorde Asset Management first reported a position in GSK in Q1 2021 and held it in 5 quarters.
Concorde Asset Management's GSK position peaked at $3.22M in Q1 2022.
900 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on Concorde Asset Management's 13F filing for Q2 2022, filed 5 Aug 2022.